Mage-a4 immtac
WebThe MAGE-A4 antigen is among the most commonly expressed cancer-testis antigens (expressed in approximately 67% of the synovial sarcomas and 34% of the MRCLS). We … WebNov 19, 2024 · Roche builds on Immunocore ImmTAC deal Extends partnership to target MAGE-A4 protein tumours Roche’s Genentech is to build on its existing partnership with T cell receptor (TCR) specialists Immunocore, and this time around the companies take aim at a certain protein type found in many solid tumours.
Mage-a4 immtac
Did you know?
WebJan 26, 2024 · It's also a key endorsement of Immunocore's ImmTac TCR platform, which can be modified to target antigens other than gp100. ... Next up are candidates targeting MAGE-A4 and PRAME, which are in ... WebAug 11, 2024 · IMC-C103C targeting MAGE-A4 In the second quarter, the Company continued to dose escalate IMC-C103C, an ImmTAC molecule targeting an HLA-A*02:01 MAGE-A4 antigen, in a first-in-human, Phase 1/2 dose escalation trial in patients with solid tumor cancers including non-small-cell lung cancer (NSCLC), gastric, head and neck, …
WebDec 9, 2024 · The trial (IMC-C103C-101) is designed to study the safety and preliminary activity of IMC-C103C as a monotherapy and in combination with atezolizumab (Tecentriq ®) in patients with MAGE-A4-expressing cancers.. David Berman, Head of Research and Development at Immunocore, commented: “We have now brought our third TCR- … WebDec 18, 2024 · Kageyama et al. reported the clinical trial results of a TCR-T therapy targeting the HLA A2402-restricted MAGE-A4 epitope NYKRCFPVI in 10 patients with recurrent …
WebJul 1, 2024 · ImmTAC molecules are first-in-class soluble T cell engagers (sTE) that use TCRs to target tumour cells. The ImmTAC platform utilises an affinity-enhanced soluble TCR, incorporating proprietary TCR technology, fused to an anti-CD3 scFv T cell engaging domain ( Fig. 1) [28]. WebDec 6, 2024 · 6 December 2024, 7:00 am · 6-min read. Immunocore announces initial Phase 1 data of ImmTAC® candidate IMC-C103C targeting MAGE-A4. Clinical activity with confirmed durable responses in ovarian cancer and a confirmed durable response in HNSCC. Manageable safety profile. Biomarkers of T cell activation consistent and robust …
WebDec 6, 2024 · Immunocore announces initial Phase 1 data of ImmTAC® candidate IMC-C103C targeting MAGE-A4 Clinical activity with confirmed durable responses in ovarian cancer and a confirmed durable...
WebHLA-A2-MAGE-A4 x CD3: solid tumors. RG6160 : cevostamab (FcRH5 x CD3) r/r multiple myeloma: RG6171. giredestrant (SERD) solid tumors. RG6114: inavolisib (mPI3K alpha inh) solid tumors: ... MAGE-A4 ImmTAC ± T. solid tumors: RG6292. CD25 MAb ± T: solid tumors. RG6323 : IL15/IL15Ra-Fc ±T. solid tumors : RG6330. KRAS G12C: solid tumors. … courtyard marriott bensalemWebMay 25, 2024 · IMC-C103C is an ImmTAC being investigated against MAGE-A4, which is among the most commonly expressed cancer testis antigens in solid malignancies, but … brian tolle artistWebNov 19, 2024 · Roche builds on Immunocore ImmTAC deal . Extends partnership to target MAGE-A4 protein tumours. 19th November 2024. Roche’s Genentech is to build on its existing partnership with T cell receptor (TCR) specialists Immunocore, and this time around the companies take aim at a certain protein type found in many solid tumours. brian tomblinWebDec 6, 2024 · Immunocore announces initial Phase 1 data of ImmTAC® candidate IMC-C103C targeting MAGE-A4 Clinical activity with confirmed durable responses in ovarian … courtyard marriott buckhead atlanta georgiaWebNov 19, 2024 · Andrew Hotchkiss, CEO of Immunocore, said: “MAGE-A4 is a known cancer-associated antigen expressed in a wide range of malignancies. Genentech is a leader in … brian t olsavsky net worthWebDec 1, 2024 · IMC-C103C is an ImmTAC being investigated against MAGE-A4, which is among the most commonly expressed cancer testis antigens in solid malignancies, but with minimal to absent expression on... courtyard marriott buena vistaWebJan 26, 2024 · On December 6, 2024, the company announced initial Phase I data for another of its pipeline products, IMC-C103C, a bispecific T cell engager targeting MAGE-A4 for advanced solid tumors. This drug was developed with Immunocore’s ImmTAC technology platform and in partnership with Genentech, a Roche company. brian toliver quitman